Indeed, multiple studies have successfully demonstrated that early treatment with the MAO-B inhibitors selegiline or lazabemide is capable to delay the need to start with levodopa in PD patients [4,8,9,17-19]. This evidence concerns the gene MAOB and Parkinson disease.